<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>One-Pager: A Novel Gene Therapy Platform for T1D</title>
  <style>
    body {
      font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
      background-color: #ffffff;
      color: #2c3e50;
      margin: 0;
      padding: 50px 40px;
      line-height: 1.6;
      max-width: 850px;
      margin: auto;
      border: 1px solid #e0e0e0;
    }
    .header {
      text-align: center;
      margin-bottom: 40px;
    }
    h1 {
      color: #0d6efd;
      font-size: 1.8rem;
      margin-bottom: 5px;
    }
    .header p {
      font-size: 1rem;
      color: #6c757d;
      margin: 0;
    }
    h2 {
      font-size: 1.1rem;
      color: #0d6efd;
      margin-top: 30px;
      border-bottom: 2px solid #0d6efd;
      padding-bottom: 6px;
      text-transform: uppercase;
      letter-spacing: 0.5px;
    }
    p {
      font-size: 1rem;
      margin-bottom: 15px;
    }
    ul {
      padding-left: 20px;
      list-style-type: '✓ ';
    }
    ul li {
      margin-bottom: 8px;
      padding-left: 8px;
    }
    .highlight-box {
      background-color: #e9f3ff;
      padding: 15px 20px;
      border-left: 5px solid #0d6efd;
      border-radius: 6px;
      margin: 25px 0;
    }
    .highlight-box strong {
      color: #0b5ed7;
    }
    .contact {
      font-size: 0.95rem;
      margin-top: 40px;
      color: #555;
      text-align: center;
      border-top: 1px solid #ddd;
      padding-top: 20px;
    }
  </style>
</head>
<body>
  <div class="header">
    <h1>A Novel Gene Therapy Platform for Type 1 Diabetes</h1>
    <p>A Preclinical Opportunity to Pioneer a Potentially Curative, One-Time Therapy</p>
  </div>

  <h2>The Unmet Need</h2>
  <p>Type 1 Diabetes (T1D) is a chronic autoimmune disease with no cure, impacting over 9 million people globally. Current treatments manage symptoms but fail to address the underlying autoimmune attack, creating a significant market for a transformative, disease-modifying therapy.</p>

  <h2>The Proposed Innovation</h2>
  <p>We have architected a comprehensive protocol for a one-time therapy using a patient's own hematopoietic stem cells (HSCs), engineered with a dual CRISPR-editing strategy:</p>
  <ul>
    <li><strong>CTLA4 Enhancement (Gain-of-Function):</strong> Designed to boost regulatory T-cell (Treg) function for systemic immune tolerance.</li>
    <li><strong>PD-1 Knockout:</strong> Aims to prevent T-cell exhaustion, allowing the immune system to re-establish balance.</li>
  </ul>
  <p>This approach is designed to create a lasting "immune reset," with the goal of protecting pancreatic beta cells from autoimmune destruction.</p>

  <h2>Strategic Value & Differentiators</h2>
  <ul>
    <li><strong>First-in-Class Approach:</strong> Targets the immune system's origin (HSCs) rather than downstream effects.</li>
    <li><strong>Platform Potential:</strong> The core IP is adaptable to other major autoimmune diseases (e.g., MS, Lupus) and immuno-oncology.</li>
    <li><strong>Translation-Ready Design:</strong> The protocol is meticulously structured with GMP and regulatory pathways in mind, facilitating a streamlined development timeline.</li>
  </ul>

  <div class="highlight-box">
    <strong>Opportunity & Deal Structure:</strong><br>
    This preclinical IP is available for exclusive licensing or acquisition. The proposed financial structure is designed for significant mutual upside, featuring multi-million dollar upfront and milestone payments, plus double-digit royalties on net sales.
  </div>

  <h2>Next Steps</h2>
  <p>The complete investment package, including a detailed pitch deck, scientific protocol, and IP declaration, is available for review upon execution of a Non-Disclosure Agreement (NDA).</p>

  <div class="contact">
    <p><strong>Contact:</strong> Abdullah M. Doumi | Protocol Architect & Innovator</p>
    <p><strong>Email:</strong> <a href="mailto:abdullah.crispr.project1@outlook.com">abdullah.crispr.project1@outlook.com</a> | <strong>GitHub:</strong> <a href="https://github.com/AbdullahDoumi" target="_blank">AbdullahDoumi</a></p>
  </div>
  <style>
	  .footer {
		text-align: center;
		margin-top: 60px;
		padding-top: 20px;
		border-top: 1px solid #e9ecef; /* Replaced var(--border-color) */
		font-size: 0.9rem;
		color: #6c757d; /* Replaced var(--secondary-text) */
		font-family: 'Inter', sans-serif, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, Helvetica, Arial;
	  }
	  .footer a {
		color: #0d6efd; /* Replaced var(--primary-blue) */
		text-decoration: none;
		font-weight: 600;
	  }
	  .footer a:hover {
		text-decoration: underline;
	  }
	</style>

	<footer class="footer">
	  <p>Copyright © 2025 Abdullah M. Doumi. All Rights Reserved.</p>
	  <p>This document is part of a proprietary conceptual framework. Its use is governed by the terms outlined in the LICENSE file.
		 <!-- Important: Replace the link below with the actual link to your LICENSE file on GitHub -->
		 <a href="https://github.com/Abdullah-jo/T1D-Cure-Protocol-Concept/blob/main/LICENSE.md" target="_blank">View License</a>
	  </p>
	</footer>
</body>
</html>